Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 23:11:603-611.
doi: 10.2147/CCID.S180904. eCollection 2018.

A 10-point plan for avoiding hyaluronic acid dermal filler-related complications during facial aesthetic procedures and algorithms for management

Affiliations

A 10-point plan for avoiding hyaluronic acid dermal filler-related complications during facial aesthetic procedures and algorithms for management

Izolda Heydenrych et al. Clin Cosmet Investig Dermatol. .

Abstract

The recent rapid growth in dermal filler use, in conjunction with inadequate product and injector control, has heralded a concerning increase in filler complications. The 10-point plan has been developed to minimize complications through careful preconsideration of causative factors, categorized as patient, product, and procedure related. Patient-related factors include history, which involves a preprocedural consultation with careful elucidation of skin conditions, systemic disease, medications, and previous cosmetic procedures. Other exclusion criteria include autoimmune diseases and multiple allergies. The temporal proximity of dental or routine medical procedures is discouraged. Insightful patient assessment, with the consideration of ethnicity, gender, and generational needs, is of paramount importance. Specified informed consent is vital due to the concerning increase in vascular complications, which carry the risk for skin compromise and loss of vision. Informed consent should be signed for both adverse events and their treatment. Product-related factors include reversibility, which is a powerful advantage when using hyaluronic acid (HA) products. Complications from nonreversible or minimally degradable products, especially when layered over vital structures, are more difficult to control. Product characteristics such as HA concentration and proprietary cross-linking should be understood in the context of ideal depth, placement, and expected duration. Product layering over late or minimally degradable fillers is discouraged, while layering of HA of over the same brand, or even across brands, seems to be feasible. Procedural factors such as photographic documentation, procedural planning, aseptic technique, and anatomical and technical knowledge are of pivotal importance. A final section is dedicated to algorithms and protocols for the management and treatment of complications such as hypersensitivity, vascular events, infection, and late-onset nodules. The 10-point plan is a systematic, effective strategy aimed at reducing the risk of dermal filler complications.

Keywords: assessment; complications; dermal fillers; prevention; treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Department of Health Review of the Regulation of Cosmetic Interventions. 2013. [Accessed September 26, 2018]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/fil... https://www.gov.uk/government/uploads/system/uploads/attachment_data/fil....
    1. Signorini M, Liew S, Sundaram H, et al. Global Aesthetics Consensus: Avoidance and Management of Complications from Hyaluronic Acid Fillers-Evidence- and Opinion-Based Review and Consensus Recommendations. Plast Reconstr Surg. 2016;137(6):961e–971e. - PMC - PubMed
    1. Bailey SH, Cohen JL, Kenkel JM. Cosmetic medicine review article: Etiology, prevention, and treatment of dermal filler complications. Aesthetic Surg J. 2011;31(1):110–121. - PubMed
    1. Ibrahim O, Overman J, Arndt KA, Dover JS. Filler nodules: Inflammatory or infectious? A Review of biofilms and their implications on clinical practice. Dermatologic Surg. 2017;44(1):53–60. - PubMed
    1. Chiang YZ, Pierone G, Al-Niaimi F. Dermal Fillers: pathophysiology, prevention and treatment of complications. J Eur Acad Dermatol Venereol. 2017;31(3):405–413. - PubMed